CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease (Q42924584)

11 November 2017

0 references

CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease (English)

1 reference

11 November 2017

Robert L Sutherland

1

1 reference

11 November 2017

Elizabeth A Musgrove

series ordinal

2

1 reference

11 November 2017

7 December 2009

1 reference

11 November 2017

Breast Cancer Research

1 reference

11 November 2017

11

1 reference

11 November 2017

6

1 reference

11 November 2017

112

1 reference

https://scigraph.springernature.com/pub.10.1186/bcr2454

11 November 2017

0 references

cites work

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2815549

Biological determinants of endocrine resistance in breast cancer

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2815549

The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2815549

Targeting cyclins and cyclin-dependent kinases in cancer: lessons from mice, hopes for therapeutic applications in human

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2815549

Cyclin D1 in breast cancer pathogenesis

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2815549

Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2815549

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2815549

Development of cell-cycle inhibitors for cancer therapy

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2815549

A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6.

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2815549

Proliferation of cancer cells despite CDK2 inhibition.

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2815549

Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2815549

Cyclins and breast cancer

1 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20067604

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/BCR2454

1 reference

Dimensions Publication ID

11 November 2017

0 references

1 reference

11 November 2017

PubMed publication ID

20067604

1 reference